Next Article in Journal
Previous Article in Journal
Pharmaceutics 2011, 3(4), 680-705; doi:10.3390/pharmaceutics3040680
Review

Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs

,  and *
Received: 11 August 2011; in revised form: 29 August 2011 / Accepted: 8 October 2011 / Published: 12 October 2011
View Full-Text   |   Download PDF [777 KB, uploaded 12 October 2011]   |   Browse Figures
Abstract: Uptake transporters (e.g., members of the SLC superfamily of solute carriers) and export proteins (e.g., members of the ABC transporter superfamily) are important determinants for the pharmacokinetics of drugs. Alterations of drug transport due to concomitantly administered drugs that interfere with drug transport may alter the kinetics of drug substrates. In vitro and in vivo studies indicate that many drugs used for the treatment of metabolic disorders and cardiovascular diseases (e.g., oral antidiabetic drugs, statins) are substrates for uptake transporters and export proteins expressed in the intestine, the liver and the kidney. Since most patients with type 2 diabetes receive more than one drug, transporter-mediated drug-drug interactions are important molecular mechanisms leading to alterations in oral antidiabetic drug pharmacokinetics with the risk of adverse drug reactions. This review focuses on uptake transporters of the SLCO/SLC21 (OATP) and SLC22 (OCT/OAT) family of solute carriers and export pumps of the ABC (ATP-binding cassette) transporter superfamily (especially P-glycoprotein) as well as the export proteins of the SLC47 (MATE) family and their role for transporter-mediated drug-drug interactions with oral antidiabetic drugs.
Keywords: oral antidiabetic drug; organic cation transporter (OCT); organic anion transporting polypeptide (OATP); multidrug and toxin extrusion protein (MATE); ABC (ATP-binding cassette) transporter; P-glycoprotein; drug-drug interaction oral antidiabetic drug; organic cation transporter (OCT); organic anion transporting polypeptide (OATP); multidrug and toxin extrusion protein (MATE); ABC (ATP-binding cassette) transporter; P-glycoprotein; drug-drug interaction
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Klatt, S.; Fromm, M.F.; König, J. Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs. Pharmaceutics 2011, 3, 680-705.

AMA Style

Klatt S, Fromm MF, König J. Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs. Pharmaceutics. 2011; 3(4):680-705.

Chicago/Turabian Style

Klatt, Sabine; Fromm, Martin F.; König, Jörg. 2011. "Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs." Pharmaceutics 3, no. 4: 680-705.



Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert